Inventiva shares are trading higher after the company announced its Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD achieved its primary efficacy endpoint.
Portfolio Pulse from Benzinga Newsdesk
Inventiva announced that its Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD achieved its primary efficacy endpoint, leading to a rise in its share price.
June 13, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's shares are trading higher after the successful Phase II clinical trial of lanifibranor in T2D and NAFLD patients.
The successful Phase II clinical trial of lanifibranor in T2D and NAFLD patients indicates positive progress in Inventiva's product pipeline. This achievement of the primary efficacy endpoint is likely to boost investor confidence in the company's potential, leading to a short-term increase in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100